首页|Pregnancy and Metabolic-associated Fatty Liver Disease: A Clinical Update

Pregnancy and Metabolic-associated Fatty Liver Disease: A Clinical Update

扫码查看
The intricate relationship between metabolic-associated fatty liver disease (MAFLD) and maternal complications has rapid- ly become a significant health threat in pregnant women. The presence of MAFLD in pregnancy increases the maternal risk of metabolic complications and comorbidities for both moth- er and baby. The preexistence or development of MAFLD in pregnancy is a complex multifactorial disorder that can lead to further complications for mother and baby. Therefore, as pregnant women are severely underrepresented in clinical research, there is a great need for a fair inclusion of this group in clinical trials. This review aims to explore the ef- fects of MAFLD during pregnancy in the context of maternal complications and outcomes and explore the effects of preg- nancy on the development and progression of MAFLD within the context of maternal obesity, altered metabolic profiles, gestational diabetes and altered hormonal profiles. We also addressed potential implications for the presence of MAFLD during pregnancy and its management in the clinical setting.

Metabolic-associated fatty liver diseasePregnancyMaternal com-plicationsFatty liver

Sherouk Fouda、Madhu Mathew Vennikandam、Joseph M.Pappachan、Cornelius J.Fernandez

展开 >

School of Health and Biomedical Sciences,RMIT University,Melbourne,VIC,Australia

Department of Gastroenterology and Hepatology,Sparrow Hospital,Michigan State University College of Human Medicine,Lansing,MI,USA

Department of Endocrinology and Metabolism,Lancashire Teaching Hospitals NHS Trust,Preston,UK

Faculty of Science,Manchester Metropolitan University,Manchester,UK

Faculty of Biology,Medicine and Health,The University of Manchester,Manches-ter,UK

Department of Endocrinology&Metabolism,Pilgrim Hospital,Boston,UK

展开 >

2022

临床与转化肝病杂志(英文版)

临床与转化肝病杂志(英文版)

ISSN:
年,卷(期):2022.10(5)
  • 92